公开(公告)号：US20240350663A1

公开(公告)日：2024-10-24

申请号：US18684886

申请日：2022-08-21

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Anna Nikolaevna STRELKOVA ,  Tatiana Evgenievna SHUGAEVA ,  Pavel Mikhailovich GERSHOVICH ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K48/00 ,  C07K14/005 ,  C12N15/86

CPC classification number: A61K48/0041 ,  C07K14/005 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: The present application relates to the fields of gene therapy and molecular biology. More specifically, the present invention relates to an isolated modified capsid protein VP1 from adeno-associated virus serotype 9 (AAV9) comprising one or more amino acid substitutions compared to the wild-type AAV9 capsid protein VP1, which substitutions increase the efficiency of production (assembly) of the vector based on recombinant adeno-associated virus serotype 9 (rAAV9), to a capsid and a vector based on the above VP1, as well as to uses thereof.

公开(公告)号：US20230321220A1

公开(公告)日：2023-10-12

申请号：US18043354

申请日：2021-08-27

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Alexander Vladimirovich PROKOFYEV ,  Pavel Mikhailovich GERSHOVICH ,  Anna Nikolaevna STRELKOVA ,  Natalia Aleksandrovna SPIRINA ,  Diana Aleksandrovna KONDINSKAIA ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12

CPC classification number: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071 ,  C12N2750/14143 ,  A61K2039/5256

Abstract: The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated vims serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

公开(公告)号：US20240076691A1

公开(公告)日：2024-03-07

申请号：US18280338

申请日：2022-03-05

Applicant: JOINT STOCK COMPANY «BIOCAD» ,  LIMITED LIABILITY COMPANY «ANABION»

Inventor： Alexander Vladimirovich PROKOFYEV ,  Pavel Mikhailovich GERSHOVICH ,  Anna Nikolaevna STRELKOVA ,  Natalia Aleksandrovna SPIRINA ,  Tatiana Evgenievna SHUGAEVA ,  Dmitry Valentinovich MOROZOV

IPC: C12N15/86 ,  A61K48/00 ,  A61P7/04 ,  C12N9/64

CPC classification number: C12N15/86 ,  A61K48/005 ,  A61P7/04 ,  C12N9/644 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12Y304/21022

Abstract: The present application relates to the fields of genetics, gene therapy, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid that encodes the FIX (coagulation factor IX) protein, an expression cassette and a vector based thereon, as well as an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for increasing the expression of the FIX gene in target cells, and use thereof.